The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##

Described herein are novel methods of synthesizing 2-amino-5-chloro-N,3-dimethylbenzamide. Compounds prepared by the methods disclosed herein are useful for preparation of certain anthranilamide compounds that are of interest as insecticides, such as, for example, the insecticides chlorantraniliprole and cyantraniliprole.

Described herein are novel methods of synthesizing 2-amino-5-chloro-N,3-dimethylbenzamide. Compounds prepared by the methods disclosed herein are useful for preparation of certain anthranilamide compounds that are of interest as insecticides, such as, for example, the insecticides chlorantraniliprole and cyantraniliprole.

This invention is directed to selective androgen receptor degrader (SARD) compounds including heterocyclic rings and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Isatin derivatives, and methods of using isatin and isatin derivatives as photoinitiators, are described.

One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.

One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.

The present disclosure provides a compound configured to release nitric oxide (NO) and inhibit the activity of a phosphodiesterase (PDE) when administered to a subject. The compound may include L.sub.1 and L.sub.2. L.sub.1 may include a functional group that is part or all of a NO releasing agent. L.sub.2 may include a functional group that is part or all of a PDE inhibitor. The compound may further include a bond or a biradical that connects L.sub.1 and L.sub.2. The present disclosure further provides a method of treating or preventing a disease using the compound or a composition including the compound.

The present disclosure provides a compound configured to release nitric oxide (NO) and inhibit the activity of a phosphodiesterase (PDE) when administered to a subject. The compound may include L.sub.1 and L.sub.2. L.sub.1 may include a functional group that is part or all of a NO releasing agent. L.sub.2 may include a functional group that is part or all of a PDE inhibitor. The compound may further include a bond or a biradical that connects L.sub.1 and L.sub.2. The present disclosure further provides a method of treating or preventing a disease using the compound or a composition including the compound.

The invention provides compounds of the formula: ##STR00001##
and salts thereof that are useful as intermediates for preparing corresponding compounds of formula I: ##STR00002##
that are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).